← Back
Data updated: Mar 10, 2026
NOVEN
OncologyMetabolicImmunology
NOVEN is a specialty pharmaceutical company focused on Oncology, Metabolic, Immunology. Key products include MINIVELLE.
1996
Since
7
Drugs
-
Trials
15
Approved (2yr)
Recent Activity
FENTANYL-75 2025-12-22
Labeling
FENTANYL-75 2025-12-22
Labeling
FENTANYL-100 2025-12-22
Labeling
FENTANYL-75 2025-12-22
Labeling
FENTANYL-75 2025-12-22
Labeling
FENTANYL-100 2025-12-22
Labeling
NITROGLYCERIN 2025-12-18
NITROGLYCERIN 2025-04-15
NITROGLYCERIN 2024-12-16
NITROGLYCERIN 2024-11-29
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 44%
0 drugs Phase 3: 13 Phase 2: 14 Phase 1: 43
Metabolic 25%
0 drugs Phase 3: 11 Phase 2: 8 Phase 1: 9
Immunology 11%
0 drugs Phase 3: 5 Phase 2: 5 Phase 1: 2
Ophthalmology 11%
0 drugs Phase 3: 3 Phase 2: 6 Phase 1: 6
Cardiovascular 10%
1 drugs Phase 3: 3 Phase 2: 4 Phase 1: 1
Pipeline Strength Pro
Loading...
Competitors Pro
Novartis big-pharma
Oncology, Cardiovascular, Immunology, Ophthalmology
Merck big-pharma
Oncology, Cardiovascular, Immunology, Metabolic
Johnson & Johnson big-pharma
Oncology, Immunology, Cardiovascular, Metabolic
Bayer big-pharma
Oncology, Cardiovascular, Ophthalmology, Metabolic
AstraZeneca big-pharma
Oncology, Cardiovascular, Metabolic, Immunology
Discontinued (1)
Company Info
- First Approval
- 1996-05-21
- Latest
- 2024-02-15
- Applications
- 6